A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.
MedPage Today on MSN
Color blindness and bladder cancer: A bad combination for survival?
People with color vision deficiency -- commonly known as color blindness -- may have a higher risk of mortality from bladder ...
Everyday Health on MSN
How to protect your kidney health if you have metastatic bladder cancer
If you have metastatic bladder cancer, you may also be at higher risk for kidney problems, including acute kidney injuries ...
The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
News Nation on MSN
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA
Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...
News-Medical.Net on MSN
Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies
Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results